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We present the results of bronchoalveolar lavage (BAL) performed in three patients with severe influenza A/H1N1 pneumonia
complicated by acute respiratory distress syndrome (ARDS). Light microscopy analysis of BAL cytocentrifugates showed the
presence of characteristic large, mononuclear, plasmoblastic/plasmocytoid-like cells never described before. Via transmission
electron microscopy, these cells were classified as atypical type II pneumocytes and some of them showed cytoplasmic vesicles
and inclusions. We concluded that plasmoblastic/plasmocytoid-like type II pneumocytes might represent a morphologic marker
of A/H1N1 influenza virus infection as well as reparative cellular activation after diffuse alveolar damage.
1. Introduction
Several studies reported histophatological observations dur-
ing influenza A/H1N1 2009 pneumonia: the major finding
was diffuse alveolar damage (DAD) [1–4]. Type II pneumo-
cytes were considered the main target of influenza A/H1N1
infection [5]. A limited number of observations described
in vivo samples, such as bronchoalveolar lavage (BAL) [6–
8]. BAL may be useful for cytological analysis in influenza
virus pneumonias. Therefore, it may play a role in further
understanding the pathogenesis of new viral strains.
In this case series we present the results of BALperformed
in three patients with severe influenza A/H1N1 2009 pneu-
monia complicated by acute respiratory distress syndrome
(ARDS).
2. Materials and Methods
Between August and December 2009 we performed a
bronchoscopy-guided BAL of three patients admitted to the
San Gerardo Hospital, Monza, Italy, for influenza A/H1N1
virus pneumonia with subsequent development of ARDS.
All three patients required intensive care unit (ICU) admis-
sion and received mechanical ventilation (MV) and extra-
corporeal respiratory support (ECMO). Influenza A/H1N1
diagnosis was confirmed by A/H1N1 virus RNA detection
on nasal swab samples using Influenza A/H1N1 2009 rRT-
PCR (real-time Reverse-Transcriptase-Polymerase-Chain-
Reaction) assay (Genexpert).
BAL differential cell count on cytocentrifugate was per-
formed in the light microscopy (LM) by counting about 300
cells in random fields at 400x magnification. Morphological
characteristics of cells were registered after May Grunwald
Giemsa and Papanicolau staining. Additional immunocy-
tochemical analyses were performed on two samples using
CD20 and CD138. Semithin sections were prepared for
transmission electron microscopy (EM) observations.
3. Results
Demographics, comorbidities, severity on admission, micro-
biological isolations, and outcome for each patient are
described in Table 1.
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Table 1: Demographics, comorbidities, severity on admission, clinical course, microbiological isolations, and outcome.
Patient 1 Patient 2 Patient 3
Age 51 43 24
Gender Male Female Male
BMI 27 32 24
Immunosuppression No No No
Comorbidities Gout
Hypothyroidism,
depression, chronic
headache
None
SOFA score on admission 6 4 6
CURB-65 score on admission 0 1 2
Hospital day when MV was started 3rd 2nd 2nd
Hospital day when ECMO was started 7th 2nd 4th
Length of ECMO (days) 20 26 15
Hospital day when influenza virus assay
was performed and oseltamivir started 3rd 2nd 1st
Length of oseltamivir therapy (days) 13 9 30
Nosocomial pathogens isolated
C. parapsilosis on throat
specimen and S.
epidermidis on BAS
P. aeruginosaMDR, C.
albicans, C. glabrata, and
C. parapsilosis on BAS
P. aeruginosaMDR,
Flavobacterium, and C.
indologenes on BAS
LP and SP urinary antigens Negative Negative Negative
CP, MP, and LP IgM and IgG Negative Negative Negative
Outcome Alive Alive Alive
MV: mechanical ventilation; ECMO: extracorporeal membrane oxygenation; LP: L. pneumophila; SP: S. pneumoniae; CP: C. pneumoniae; MP:M. pneumoniae;
BAS: bronchial aspirate; MDR: multidrug resistant (used for pathogens resistant to at least three drugs from different antibiotic categories).
Table 2: Cytological examination of the bronchoalveolar lavage.
Patient #1 Patient #2 Patient #3 Reference intervals#
Day after hospitalization BAL was performed 15th 6th 5th
Alveolar macrophages % 36 31 33 80–90%
Lymphocytes % 46 15 21 5–15%
Neutrophils, % 3 44 38 1–3%
Mast cells % 6 0 2 <1%
Eosinophils % 2 1 1 ≤1%
p/p-like cells % 8 9 6 Absent
Red blood cells Present Present Present Absent
Type II pneumocytes aggregated in clusters Absent Present Present Absent
p/p-like cells: plasmoblastic/plasmocytoid-like cells.
#BAL Cooperative Group Steering Committee. Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis, and selected com-
parison groups [9].
Antiviral therapy with Oseltamivir (150mg twice daily)
was started at hospital admission simultaneously with rRT-
PCR assay and was continued until rRT-PCR assay on nasal
swab turned negative.
BAL cytocentrifugates analyses are summarized in
Table 2. Large, atypical cells with plasmocytoid appearance
were observed in all three specimenswith similar percentages
(8, 9, and 6%, resp.). At LM, they appeared as large,
plasmoblastic/plasmocytoid-like cells with eccentric nuclei
and paranuclear vacuoles, high ratio nucleus/cytoplasm, and
intensely basophilic cytoplasm. No clear viral cytopathic
effect was observed (Figure 1). Immunocytochemical analysis
on cytocentrifugate showed that these cells were negative
for CD20 (B lymphocyte marker) and CD138 (plasma cell
marker).
Ultrastructural examinations at transmission EMallowed
us to observe multilamellar osmiophilic bodies in the cyto-
plasm of plasmoblastic/plasmocytoid-like cells. Osmiophilic
bodies produce surfactant and are specific for type II pneu-
mocytes. Therefore, these cells were classified as atypical
type II pneumocytes. EM showed in these cells small round
cytoplasmic inclusions with irregular surface and a diameter
around 60 nm (Figure 2). They also showed cytoplasmic
vesicles with a diameter around 100 nm and an irregular
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Figure 1: Specimen from bronchoalveolar lavage displays some
macrophages, neutrophilic granulocytes, and large plasmoblastic/
plasmocytoid-like elements (arrow) with basophilic cytoplasm and
paranuclear vacuole (May Grunwald Giemsa, magnification ×400).
200nm
Figure 2: Ultrastructural examination of atypical type II pneu-
mocytes from bronchoalveolar lavage specimen. Arrows indicate
suspected cytoplasmic viral inclusions. Scale bar: 200 nm.
electron-dense core (Figure 3). These aspects were suspected
to be viral inclusions.
4. Discussion
The main characteristic of the BAL of our patients with
influenza A/H1N1 pneumonia associated with ARDS was the
presence of large cells with a plasmoblastic/plasmocytoid-like
appearance, identified at EM as atypical type II pneumocytes.
We postulate two possible explanations for the presence
of these atypical cells.
The first hypothesis regards the reparative action that
type II pneumocytes may have in DAD. In our cases,
type II pneumocytes activation would be justified by viral
damage to alveolar epithelium. Reactive hyperplasia of type
II pneumocytes is typical of the organizing stage of ARDS.
Stanley described morphological atypias, such as increased
nuclear-cytoplasmic ratio, in type II pneumocytes found in
BALs during ARDS [10]. These atypical pneumocytes are
usually aggregated in clusters and are supposed to have a
reparative role.
All our patients developed ARDS and we observed pneu-
mocytes aggregated in clusters in the BALs performed earlier
Figure 3: Ultrastructural examination of atypical type II pneu-
mocytes from bronchoalveolar lavage specimen. Arrow indicates a
vesicle containing a suspected viral particle. Scale bar: 200 nm.
(cases numbers 2 and 3). According to this first hypothesis,
the atypical cells we observed could be described as reactive
immature type II pneumocytes.
The second hypothesis regards influenza A/H1N1 virus
cytopathic effect. Type II pneumocytes have been described
as the main target of influenza A/H1N1 2009 infection [5].
Nakajima et al. in 2012 described four autopsy cases of
influenza A/H1N1 with a histopathological pattern of acute
DAD who presented with influenza virus antigen-positive
type II pneumocytes, perhaps indicating a direct role of the
virus-infected cells in the acute alveolar damage [11]. No
specific cytophatic effect or viral inclusion has been described
so far at LM in lung tissue specimens during influenza
pneumonia [1].
Several observations have been performed via EM on
autopsy specimens. During the recent influenza pandemic,
Mauad et al. found type II pneumocyteswith vesicles, approx-
imately 100 nm in diameter, with an electron-dense center
[2]. Bal and colleagues described cytoplasmic inclusions in
pneumocytes, which ranged in diameter from 74 to 82 nm
and showed surface spikes characteristic of influenza virus
[12].
EMobservations of our specimens revealed some atypical
pneumocytes showing both small round cytoplasmic inclu-
sions with an irregular surface and small vesicles (similar to
those described by Bal andMauad). According to this second
hypothesis, atypical type II pneumocytes could be a specific
morphological marker of influenza virus infection.
From the data collected so far, we cannot favor one expla-
nation; in fact, they could coexist in cases of severe influenza
A/H1N1 pneumonia associated with ARDS.
Limitations of the present study include the following:
first, the paucity of cases analyzed; second, we did not
perform immunohistochemical staining for H1N1 antigens
on BAL samples.
The description of BAL in a control group of patients with
ARDS not associated with H1N1 pneumonia is beyond the
scope of this case series. However, other authors described
BAL cytology in non-H1N1 ARDS, and although they
reported morphological atypias in type II pneumocytes, they
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did not describe these peculiar plasmoblastic/plasmocytoid-
like cells [10, 12, 13].
The collection of the airway specimens of patients num-
ber 2 and number 3, in which the nosocomial pathogens were
isolated, took place after BALwas performed.Therefore, these
pathogens most likely did not affect the cellularity in BAL.
In conclusion, plasmoblastic/plasmocytoid-like type II
pneumocytes characterize the BAL of our patients with
influenza A/H1N1 2009 pneumonia associated with ARDS.
They could represent a pathognomonic marker of influenza
virus pneumonia as well as reparative cellular activation
after DAD. More observations of BAL cytology in patients
with influenza pneumonia are needed to understand their
characteristics and role.
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